BiotechTube
IBSS Biomed

IBSS Biomed

Warsaw, Poland· Est.
biomed.pl
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.2M

Overview

IBSS Biomed is a well-established, revenue-generating Polish biotech firm with an 80-year legacy in vaccine production. It operates a diversified business model encompassing therapeutics (vaccines, OTC drugs), diagnostics, and specialized probiotics, with a strong focus on epidemiological security for Poland. The company possesses proprietary technology platforms, controls its own manufacturing from API to finished product, and has a significant international commercial footprint. Its strategy combines serving national public health programs with global commercial expansion and R&D in areas like novel probiotics.

Infectious DiseaseGastrointestinalSupportive Care

Technology Platform

Proprietary bacterial/viral antigen manufacturing for vaccines; specialized probiotic strain cultivation and fermentation technology, including production of antimicrobial supernatants; integrated GMP manufacturing from API to finished product.

Funding History

1
Total raised:$1.2M
Grant$1.2M

Opportunities

Growing demand for regional vaccine manufacturing sovereignty in Europe post-pandemic creates a strategic advantage.
The global expansion of the specialized probiotics and OTC health markets offers significant avenues for revenue growth through export.
Its unique, world-only Pseudomonas aeruginosa vaccine addresses a clear unmet medical need in hospital-acquired infections, representing a valuable niche asset.

Risk Factors

Revenue concentration risk from dependence on the Polish National Immunization Program contracts.
Intense competition from large multinational pharmaceutical companies with greater R&D resources in both vaccines and probiotics.
Operational risks associated with maintaining stringent regulatory compliance for biological manufacturing across multiple product lines and markets.

Competitive Landscape

Competes in vaccines against global giants (GSK, Pfizer, Sanofi) and other regional producers, differentiating via niche products and national supplier role. In probiotics, faces competition from large consumer health companies (Probi, Chr. Hansen) and pharmaceutical firms, competing on proprietary, population-specific strains. Its diversified OTC/diagnostic portfolio places it against numerous pharmaceutical and medtech companies in Central Europe.

More companies in Biologics / Biosimilars →More companies in Poland →